Skip over navigation
Directory
Directory Search
Jobs
Job Search
Post a Job
Patient
Patient Resources
Drug Development
History
Genealogy
Toons & Teasers
About
Advertising
Home
Quick Links
Directory
Job Search
Toons & Teasers
Advertising
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Industry News
Search Articles:
Alkermes announces initiation of phase 1 clinical study of immuno-oncology drug candidate
Alkermes announced initiation of a phase 1 clinical study of the company’s immuno-oncology drug candidate, ALKS 4230, a novel Selective Effector Cell Activator (SECA™) protein designed for targeted interleukin-2 receptor activation.
May 25, 2016
More...
Email This Page
to a Friend
Print This
Page